---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-26-000036"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T06:59:35.000551+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals closes $5M private placement with Perceptive Advisors; warrants could add $19M

## Summary
- Closed private placement raising $5.0M upfront; potential $19M from warrant exercise.
- Sole investors: Perceptive Advisors and ADAR1 Capital Management; no placement agent engaged.
- Each unit: 1 common share (or pre-funded warrant) + 4 Tranche A-1 + 1 Tranche A-2 warrants at $2.543.
- All warrants exercisable at $1.94/share; A-1 term ≤9 months (30 days after strategic transaction), A-2 ≤4 years (30 days after Phase 3 enrollment).
- Proceeds for general corporate purposes, including R&D and business development.

## SEC filing metadata
- accession: 0001372514-26-000036
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000036/0001372514-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000036/kprx-20260403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-26-000036
- JSON: https://secwatch.observer/filing/0001372514-26-000036.json
- Plain text: https://secwatch.observer/filing/0001372514-26-000036.txt

## Source-grounded claims
- claim_id: e1b0f87296b142041e67c745fa4dd347a0effc81
  claim: KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain institutional investors valued at expected aggregate gross proceeds at closing of approximately $5.0 million and potential future warr (effective 2026-04-03).
  evidence_excerpt: On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000036/0001372514-26-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.